Progenics Pharma (PGNX) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. EXPE
5. ARM
6. QCOM
7. DDOG
8. CPAY
9. CHYM
10. W

Go back to Progenics Pharma (PGNX) Tops Q2 EPS by 5c

Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results

August 4, 2016 7:30 AM EDT

On July 19, the Company Announced FDA Approval of RELISTOR® Tablets, Triggering a $50 Million Milestone  Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results Expected Between December 2016 and March 2017Licensed PSMA Antibody Technology to Bayer and Recognition of $5 Million in Upfront and Milestone RevenuePhase 3 Study Enrollment of PSMA-Targeted SPECT/CT Imaging Agent 1404 OngoingSecond Quarter 2016 RELISTOR Subcutaneous (SC) Net Sales of $15.9 MillionOn Track to Initiate Phase 2/3 Trial for PyLTM Imaging Agent and Phase 1 Trial For 1095 This Year

NEW YORK, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.... More